

Unrelated Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	40533	13467	9789
Source of data			
CRF	22969 (57)	6449 (48)	5047 (52)
TED	17564 (43)	7018 (52)	4742 (48)
Number of centers	249	227	351
Disease at transplant			
AML	14333 (35)	5125 (38)	2773 (28)
ALL	6113 (15)	1842 (14)	1391 (14)
Other leukemia	1369 (3)	359 (3)	241 (2)
CML	3343 (8)	966 (7)	769 (8)
MDS	5816 (14)	2150 (16)	1108 (11)
Other acute leukemia	430 (1)	168 (1)	97 (1)
NHL	3306 (8)	912 (7)	1285 (13)
Hodgkin Lymphoma	576 (1)	111 (1)	471 (5)
Plasma Cell Disorders, MM	487 (1)	116 (1)	529 (5)
Other malignancies	53 (<1)	13 (<1)	23 (<1)
Breast cancer	7 (<1)	4 (<1)	1 (<1)
SAA	1319 (3)	415 (3)	330 (3)
Inherited abnormalities erythrocyte diff fxn	712 (2)	242 (2)	157 (2)
SCIDs	722 (2)	247 (2)	230 (2)
Inherited abnormalities of platelets	39 (<1)	12 (<1)	10 (<1)
Inherited disorders of metabolism	272 (1)	72 (1)	91 (1)
Histiocytic disorders	360 (1)	100 (1)	86 (1)
Autoimmune disorders	20 (<1)	11 (<1)	5 (<1)
Other	43 (<1)	15 (<1)	16 (<1)
MPN	1213 (3)	587 (4)	176 (2)
AML Disease status at transplant			
CR1	7540 (53)	2900 (57)	1297 (47)
CR2	2787 (19)	941 (18)	574 (21)
CR3+	275 (2)	71 (1)	63 (2)
Advanced or active disease	3595 (25)	1181 (23)	781 (28)
Missing	136 (1)	32 (1)	58 (2)
ALL Disease status at transplant			
CR1	3012 (49)	999 (54)	597 (43)
CR2	1750 (29)	485 (26)	405 (29)
CR3+	494 (8)	131 (7)	138 (10)
Advanced or active disease	811 (13)	213 (12)	215 (15)
Missing	46 (1)	14 (1)	36 (3)
MDS Disease status at transplant			
Early	1293 (22)	403 (19)	258 (23)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Advanced	3605 (62)	1535 (71)	599 (54)
Missing	918 (16)	212 (10)	251 (23)
NHL Disease status at transplant			
CR1	489 (15)	177 (20)	121 (9)
CR2	517 (16)	135 (15)	300 (23)
CR3+	223 (7)	53 (6)	176 (14)
PR	378 (12)	95 (11)	135 (11)
Advanced	1617 (49)	429 (47)	535 (42)
Missing	61 (2)	15 (2)	15 (1)
Recipient age at transplant			
0-9 years	3580 (9)	1008 (7)	1040 (11)
10-19 years	3695 (9)	1023 (8)	981 (10)
20-29 years	4238 (10)	1261 (9)	1123 (11)
30-39 years	4685 (12)	1376 (10)	1205 (12)
40-49 years	6191 (15)	1909 (14)	1569 (16)
50-59 years	8311 (21)	2654 (20)	1941 (20)
60-69 years	8185 (20)	3351 (25)	1682 (17)
70+ years	1648 (4)	885 (7)	248 (3)
Median (Range)	47 (0-84)	51 (0-82)	44 (0-79)
Recipient race/ethnicity			
White	33692 (83)	11191 (83)	7332 (75)
Black or African American	1856 (5)	566 (4)	422 (4)
Asian	913 (2)	432 (3)	334 (3)
Native Hawaiian or other Pacific Islander	52 (<1)	21 (<1)	20 (<1)
American Indian or Alaska Native	153 (<1)	53 (<1)	32 (<1)
Hispanic	2398 (6)	724 (5)	514 (5)
Missing	1469 (4)	480 (4)	1135 (12)
Recipient sex			
Male	23601 (58)	7870 (58)	5840 (60)
Female	16932 (42)	5597 (42)	3949 (40)
Karnofsky score			
10-80	13678 (34)	4945 (37)	3152 (32)
90-100	25258 (62)	7898 (59)	6031 (62)
Missing	1597 (4)	624 (5)	606 (6)
HLA-A B DRB1 groups - low resolution			
<=3/6	24 (<1)	68 (1)	2 (<1)
4/6	223 (1)	101 (1)	44 (<1)
5/6	5663 (14)	1602 (13)	1348 (15)
6/6	34326 (85)	10740 (86)	7865 (85)
Unknown	297 (N/A)	956 (N/A)	530 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	867 (2)	129 (1)	44 (1)
6/8	1699 (4)	120 (1)	149 (2)
7/8	7945 (20)	1648 (17)	1417 (21)
8/8	29160 (74)	7958 (81)	5116 (76)
Unknown	862 (N/A)	3612 (N/A)	3063 (N/A)
HLA-DPB1 Match			

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Double allele mismatch	10409 (30)	960 (23)	708 (27)
Single allele mismatch	18928 (54)	2148 (51)	1393 (53)
Full allele matched	5685 (16)	1082 (26)	533 (20)
Unknown	5511 (N/A)	9277 (N/A)	7155 (N/A)
High resolution release score			
No	5867 (14)	13402 (>99)	9092 (93)
Yes	34666 (86)	65 (<1)	697 (7)
KIR typing available			
No	26923 (66)	13444 (>99)	9595 (98)
Yes	13610 (34)	23 (<1)	194 (2)
Graft type			
Marrow	15196 (37)	4390 (33)	3732 (38)
PBSC	25290 (62)	8939 (66)	6024 (62)
BM+PBSC	8 (<1)	6 (<1)	4 (<1)
PBSC+UCB	22 (<1)	122 (1)	6 (<1)
Others	17 (<1)	10 (<1)	23 (<1)
Conditioning regimen			
Myeloablative	26008 (64)	7923 (59)	5727 (59)
RIC/Nonmyeloablative	14341 (35)	5502 (41)	3939 (40)
TBD	184 (<1)	42 (<1)	123 (1)
Donor age at donation			
To Be Determined/NA	141 (<1)	972 (7)	58 (1)
0-9 years	4 (<1)	30 (<1)	1 (<1)
10-19 years	1117 (3)	459 (3)	227 (2)
20-29 years	18122 (45)	5923 (44)	4048 (41)
30-39 years	11674 (29)	3474 (26)	2926 (30)
40-49 years	7258 (18)	1960 (15)	1912 (20)
50+ years	2217 (5)	649 (5)	617 (6)
Median (Range)	31 (0-69)	30 (0-109)	32 (7-61)
Donor/Recipient CMV serostatus			
+/+	10042 (25)	3748 (29)	2411 (26)
+/-	4803 (12)	1745 (13)	1255 (13)
-/+	13382 (33)	3984 (31)	2970 (32)
-/-	11741 (29)	3555 (27)	2777 (30)
CB - recipient +	1 (<1)	13 (<1)	0
CB - recipient -	0	6 (<1)	0
CB - recipient CMV unknown	0	1 (<1)	0
Unknown	564 (N/A)	415 (N/A)	376 (N/A)
GvHD Prophylaxis			
Ex vivo T-cell depletion	1126 (3)	295 (2)	319 (3)
CD34 selection	720 (2)	323 (2)	162 (2)
Post-CY + other(s)	1436 (4)	1007 (7)	346 (4)
Post-CY alone	85 (<1)	40 (<1)	20 (<1)
Tacrolimus + MMF +- others	4625 (11)	1376 (10)	986 (10)
Tacrolimus + MTX +- others (except MMF)	17633 (44)	6009 (45)	3028 (31)
Tacrolimus + others (except MTX, MMF)	2098 (5)	861 (6)	410 (4)
Tacrolimus alone	982 (2)	357 (3)	167 (2)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
CSA + MMF +- others (except Tacrolimus)	2601 (6)	664 (5)	891 (9)
CSA + MTX +- others (except Tacrolimus, MMF)	6611 (16)	1736 (13)	2476 (25)
CSA + others (except Tacrolimus, MTX, MMF)	1016 (3)	311 (2)	309 (3)
CSA alone	486 (1)	118 (1)	323 (3)
Other GVHD prophylaxis	698 (2)	235 (2)	178 (2)
Missing	416 (1)	135 (1)	174 (2)
Donor/Recipient sex match			
Male-Male	16700 (41)	5341 (40)	3950 (41)
Male-Female	10242 (25)	3299 (25)	2253 (23)
Female-Male	6825 (17)	2360 (18)	1850 (19)
Female-Female	6622 (16)	2155 (16)	1665 (17)
CB - recipient M	11 (<1)	71 (1)	0
CB - recipient F	11 (<1)	59 (<1)	7 (<1)
Unknown	122 (N/A)	182 (N/A)	64 (N/A)
Year of transplant			
1986-1990	349 (1)	45 (<1)	85 (1)
1991-1995	1822 (4)	438 (3)	634 (6)
1996-2000	3208 (8)	1141 (8)	945 (10)
2001-2005	5171 (13)	1020 (8)	1536 (16)
2006-2010	9037 (22)	1782 (13)	1701 (17)
2011-2015	12124 (30)	3304 (25)	2721 (28)
2016-2020	8822 (22)	5737 (43)	2167 (22)
Follow-up among survivors, Months			
N Eval	17002	6585	4049
Median (Range)	61 (0-365)	36 (0-362)	50 (0-365)

Refresh date: April 2021

Unrelated Cord Blood HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	5478	1400	1553
Source of data			
CRF	4139 (76)	1052 (75)	1026 (66)
TED	1339 (24)	348 (25)	527 (34)
Number of centers	148	135	205
Disease at transplant			
AML	2111 (39)	487 (35)	457 (29)
ALL	1157 (21)	303 (22)	322 (21)
Other leukemia	91 (2)	28 (2)	25 (2)
CML	121 (2)	34 (2)	35 (2)
MDS	496 (9)	135 (10)	117 (8)
Other acute leukemia	90 (2)	21 (2)	27 (2)
NHL	315 (6)	68 (5)	160 (10)
Hodgkin Lymphoma	49 (1)	21 (2)	69 (4)
Plasma Cell Disorders, MM	15 (<1)	6 (<1)	30 (2)
Other malignancies	10 (<1)	0	2 (<1)
SAA	91 (2)	30 (2)	25 (2)
Inherited abnormalities erythrocyte diff fxn	161 (3)	50 (4)	32 (2)
SCIDs	249 (5)	74 (5)	104 (7)
Inherited abnormalities of platelets	17 (<1)	5 (<1)	5 (<1)
Inherited disorders of metabolism	342 (6)	97 (7)	91 (6)
Histiocytic disorders	102 (2)	27 (2)	38 (2)
Autoimmune disorders	9 (<1)	0	1 (<1)
Other	10 (<1)	2 (<1)	4 (<1)
MPN	42 (1)	12 (1)	9 (1)
AML Disease status at transplant			
CR1	1103 (52)	268 (55)	222 (49)
CR2	578 (27)	125 (26)	126 (28)
CR3+	48 (2)	7 (1)	16 (4)
Advanced or active disease	377 (18)	84 (17)	91 (20)
Missing	5 (<1)	3 (1)	2 (<1)
ALL Disease status at transplant			
CR1	529 (46)	131 (43)	141 (44)
CR2	432 (37)	112 (37)	112 (35)
CR3+	122 (11)	41 (14)	43 (13)
Advanced or active disease	73 (6)	19 (6)	25 (8)
Missing	1 (<1)	0	1 (<1)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
MDS Disease status at transplant			
Early	157 (32)	36 (27)	53 (45)
Advanced	297 (60)	86 (64)	48 (41)
Missing	42 (8)	13 (10)	16 (14)
NHL Disease status at transplant			
CR1	56 (18)	5 (7)	18 (11)
CR2	59 (19)	17 (25)	39 (25)
CR3+	25 (8)	8 (12)	27 (17)
PR	57 (18)	9 (13)	20 (13)
Advanced	115 (37)	28 (41)	53 (33)
Missing	0	1 (1)	2 (1)
Recipient age at transplant			
0-9 years	1682 (31)	521 (37)	516 (33)
10-19 years	733 (13)	152 (11)	192 (12)
20-29 years	506 (9)	98 (7)	135 (9)
30-39 years	515 (9)	129 (9)	168 (11)
40-49 years	575 (10)	136 (10)	157 (10)
50-59 years	742 (14)	172 (12)	208 (13)
60-69 years	624 (11)	167 (12)	166 (11)
70+ years	101 (2)	25 (2)	11 (1)
Median (Range)	26 (0-83)	23 (0-76)	25 (0-78)
Recipient race/ethnicity			
White	3039 (55)	827 (59)	845 (54)
Black or African American	774 (14)	182 (13)	193 (12)
Asian	314 (6)	91 (7)	103 (7)
Native Hawaiian or other Pacific Islander	28 (1)	3 (<1)	15 (1)
American Indian or Alaska Native	39 (1)	6 (<1)	15 (1)
Hispanic	996 (18)	211 (15)	211 (14)
Missing	288 (5)	80 (6)	171 (11)
Recipient sex			
Male	3017 (55)	801 (57)	893 (58)
Female	2461 (45)	599 (43)	660 (42)
Karnofsky score			
10-80	1433 (26)	349 (25)	396 (25)
90-100	3882 (71)	958 (68)	1062 (68)
Missing	163 (3)	93 (7)	95 (6)
HLA-A B DRB1 groups - low resolution			
<=3/6	78 (1)	33 (3)	13 (1)
4/6	2177 (41)	492 (41)	586 (40)
5/6	2386 (45)	506 (42)	685 (46)
6/6	696 (13)	178 (15)	196 (13)
Unknown	141 (N/A)	191 (N/A)	73 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	2604 (55)	493 (56)	651 (55)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
6/8	1119 (24)	209 (24)	301 (25)
7/8	674 (14)	117 (13)	157 (13)
8/8	317 (7)	67 (8)	80 (7)
Unknown	764 (N/A)	514 (N/A)	364 (N/A)
HLA-DPB1 Match			
Double allele mismatch	767 (39)	80 (40)	92 (38)
Single allele mismatch	999 (51)	99 (50)	130 (53)
Full allele matched	192 (10)	19 (10)	22 (9)
Unknown	3520 (N/A)	1202 (N/A)	1309 (N/A)
High resolution release score			
No	3976 (73)	1350 (96)	1528 (98)
Yes	1502 (27)	50 (4)	25 (2)
KIR typing available			
No	4233 (77)	1394 (>99)	1533 (99)
Yes	1245 (23)	6 (<1)	20 (1)
Graft type			
UCB	5171 (94)	1278 (91)	1473 (95)
BM+UCB	1 (<1)	0	0
PBSC+UCB	279 (5)	122 (9)	71 (5)
Others	27 (<1)	0	9 (1)
Number of cord units			
1	4636 (85)	0	1260 (81)
2	838 (15)	0	293 (19)
3	2 (<1)	0	0
Unknown	2 (N/A)	1400 (N/A)	0 (N/A)
Conditioning regimen			
Myeloablative	3645 (67)	902 (64)	949 (61)
RIC/Nonmyeloablative	1824 (33)	492 (35)	597 (38)
TBD	9 (<1)	6 (<1)	7 (<1)
Donor age at donation			
To Be Determined/NA	160 (3)	78 (6)	64 (4)
0-9 years	4851 (89)	1098 (78)	1376 (89)
10-19 years	272 (5)	124 (9)	67 (4)
20-29 years	59 (1)	32 (2)	9 (1)
30-39 years	55 (1)	32 (2)	16 (1)
40-49 years	39 (1)	16 (1)	6 (<1)
50+ years	42 (1)	20 (1)	15 (1)
Median (Range)	3 (0-72)	5 (0-73)	3 (0-69)
Donor/Recipient CMV serostatus			
+/+	1246 (23)	273 (20)	326 (21)
+/-	537 (10)	136 (10)	146 (9)
-/+	1012 (18)	256 (18)	284 (18)
-/-	687 (13)	177 (13)	204 (13)
CB - recipient +	1150 (21)	298 (21)	314 (20)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
CB - recipient -	762 (14)	208 (15)	231 (15)
CB - recipient CMV unknown	84 (2)	52 (4)	48 (3)
GvHD Prophylaxis			
Ex vivo T-cell depletion	28 (1)	9 (1)	4 (<1)
CD34 selection	227 (4)	99 (7)	52 (3)
Post-CY + other(s)	9 (<1)	5 (<1)	2 (<1)
Tacrolimus + MMF +- others	1501 (27)	380 (27)	315 (20)
Tacrolimus + MTX +- others (except MMF)	203 (4)	55 (4)	64 (4)
Tacrolimus + others (except MTX, MMF)	203 (4)	53 (4)	66 (4)
Tacrolimus alone	129 (2)	37 (3)	33 (2)
CSA + MMF +- others (except Tacrolimus)	2572 (47)	578 (41)	736 (47)
CSA + MTX +- others (except Tacrolimus, MMF)	95 (2)	27 (2)	39 (3)
CSA + others (except Tacrolimus, MTX, MMF)	318 (6)	110 (8)	143 (9)
CSA alone	57 (1)	19 (1)	47 (3)
Other GVHD prophylaxis	111 (2)	17 (1)	37 (2)
Missing	25 (<1)	11 (1)	15 (1)
Donor/Recipient sex match			
CB - recipient M	3017 (55)	801 (57)	892 (57)
CB - recipient F	2461 (45)	599 (43)	660 (42)
CB - recipient sex unknown	0	0	1 (<1)
Year of transplant			
1996-2000	1 (<1)	2 (<1)	4 (<1)
2001-2005	107 (2)	84 (6)	30 (2)
2006-2010	1737 (32)	402 (29)	481 (31)
2011-2015	2464 (45)	470 (34)	694 (45)
2016-2020	1169 (21)	442 (32)	344 (22)
Follow-up among survivors, Months			
N Eval	2660	760	768
Median (Range)	62 (1-192)	49 (1-206)	52 (1-240)

Refresh date: April 2021

Related Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	8374	1232	526
Source of data			
CRF	3271 (39)	401 (33)	243 (46)
TED	5103 (61)	831 (67)	283 (54)
Number of centers	89	69	53
Disease at transplant			
AML	2760 (33)	406 (33)	152 (29)
ALL	1343 (16)	240 (19)	93 (18)
Other leukemia	175 (2)	32 (3)	17 (3)
CML	267 (3)	29 (2)	15 (3)
MDS	1088 (13)	148 (12)	73 (14)
Other acute leukemia	116 (1)	21 (2)	4 (1)
NHL	778 (9)	109 (9)	65 (12)
Hodgkin Lymphoma	173 (2)	24 (2)	18 (3)
Plasma Cell Disorders, MM	235 (3)	34 (3)	19 (4)
Other malignancies	21 (<1)	0	0
Breast cancer	1 (<1)	0	0
SAA	374 (4)	47 (4)	14 (3)
Inherited abnormalities erythrocyte diff fxn	453 (5)	61 (5)	20 (4)
SCIDs	171 (2)	27 (2)	10 (2)
Inherited abnormalities of platelets	9 (<1)	0	0
Inherited disorders of metabolism	14 (<1)	2 (<1)	2 (<1)
Histiocytic disorders	43 (1)	7 (1)	2 (<1)
Autoimmune disorders	8 (<1)	0	1 (<1)
Other	6 (<1)	0	0
MPN	339 (4)	45 (4)	21 (4)
AML Disease status at transplant			
CR1	1740 (63)	274 (67)	94 (62)
CR2	420 (15)	47 (12)	18 (12)
CR3+	29 (1)	8 (2)	1 (1)
Advanced or active disease	566 (21)	74 (18)	39 (26)
Missing	5 (<1)	3 (1)	0
ALL Disease status at transplant			
CR1	850 (63)	151 (63)	60 (65)
CR2	350 (26)	60 (25)	21 (23)
CR3+	69 (5)	10 (4)	7 (8)
Advanced or active disease	74 (6)	19 (8)	5 (5)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
MDS Disease status at transplant			
Early	189 (17)	16 (11)	15 (21)
Advanced	865 (80)	123 (83)	55 (75)
Missing	34 (3)	9 (6)	3 (4)
NHL Disease status at transplant			
CR1	136 (18)	23 (21)	11 (17)
CR2	148 (19)	21 (19)	11 (17)
CR3+	87 (11)	10 (9)	2 (3)
PR	65 (8)	13 (12)	7 (11)
Advanced	334 (43)	41 (38)	34 (52)
Missing	4 (1)	0	0
Recipient age at transplant			
0-9 years	806 (10)	104 (8)	32 (6)
10-19 years	949 (11)	107 (9)	44 (8)
20-29 years	708 (8)	134 (11)	46 (9)
30-39 years	644 (8)	110 (9)	50 (10)
40-49 years	1084 (13)	160 (13)	69 (13)
50-59 years	1895 (23)	277 (22)	122 (23)
60-69 years	1983 (24)	295 (24)	147 (28)
70+ years	305 (4)	45 (4)	16 (3)
Median (Range)	50 (0-82)	50 (0-76)	52 (0-77)
Recipient race/ethnicity			
White	5360 (64)	675 (55)	351 (67)
Black or African American	997 (12)	134 (11)	51 (10)
Asian	380 (5)	103 (8)	23 (4)
Native Hawaiian or other Pacific Islander	27 (<1)	3 (<1)	1 (<1)
American Indian or Alaska Native	33 (<1)	3 (<1)	2 (<1)
Hispanic	1220 (15)	238 (19)	75 (14)
Missing	357 (4)	76 (6)	23 (4)
Recipient sex			
Male	4918 (59)	722 (59)	312 (59)
Female	3456 (41)	510 (41)	214 (41)
Karnofsky score			
10-80	2939 (35)	508 (41)	221 (42)
90-100	5231 (62)	696 (56)	282 (54)
Missing	204 (2)	28 (2)	23 (4)
High-resolution HLA matches available out of 8			
<=5/8	1899 (25)	253 (30)	110 (30)
6/8	81 (1)	14 (2)	10 (3)
7/8	118 (2)	20 (2)	10 (3)
8/8	5403 (72)	568 (66)	235 (64)
Unknown	873 (N/A)	377 (N/A)	161 (N/A)
Graft type			
Marrow	2409 (29)	287 (23)	148 (28)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
PBSC	5914 (71)	922 (75)	368 (70)
UCB(related)	1 (<1)	10 (1)	0
BM+PBSC	6 (<1)	4 (<1)	0
BM+UCB	28 (<1)	8 (1)	1 (<1)
PBSC+UCB	0	0	9 (2)
Others	16 (<1)	1 (<1)	0
Conditioning regimen			
Myeloablative	4763 (57)	706 (57)	276 (52)
RIC/Nonmyeloablative	3566 (43)	518 (42)	243 (46)
TBD	45 (1)	8 (1)	7 (1)
Donor age at donation			
To Be Determined/NA	11 (<1)	2 (<1)	2 (<1)
0-9 years	567 (7)	70 (6)	25 (5)
10-19 years	839 (10)	109 (9)	38 (7)
20-29 years	1099 (13)	165 (13)	68 (13)
30-39 years	1116 (13)	193 (16)	93 (18)
40-49 years	1365 (16)	205 (17)	73 (14)
50+ years	3377 (40)	488 (40)	227 (43)
Median (Range)	45 (0-81)	44 (0-79)	45 (0-76)
Donor/Recipient CMV serostatus			
+/+	3403 (41)	563 (46)	208 (41)
+/-	945 (11)	99 (8)	51 (10)
-/+	2044 (25)	286 (24)	128 (25)
-/-	1857 (23)	262 (22)	118 (23)
Unknown	125 (N/A)	22 (N/A)	21 (N/A)
GvHD Prophylaxis			
Ex vivo T-cell depletion	103 (1)	32 (3)	9 (2)
CD34 selection	137 (2)	36 (3)	9 (2)
Post-CY + other(s)	1907 (23)	251 (20)	130 (25)
Post-CY alone	37 (<1)	8 (1)	4 (1)
Tacrolimus + MMF +- others	808 (10)	76 (6)	25 (5)
Tacrolimus + MTX +- others (except MMF)	3343 (40)	430 (35)	230 (44)
Tacrolimus + others (except MTX, MMF)	670 (8)	238 (19)	51 (10)
Tacrolimus alone	67 (1)	6 (<1)	1 (<1)
CSA + MMF +- others (except Tacrolimus)	216 (3)	28 (2)	9 (2)
CSA + MTX +- others (except Tacrolimus, MMF)	642 (8)	80 (6)	32 (6)
CSA + others (except Tacrolimus, MTX, MMF)	80 (1)	10 (1)	2 (<1)
CSA alone	69 (1)	9 (1)	2 (<1)
Other GVHD prophylaxis	123 (1)	14 (1)	10 (2)
Missing	172 (2)	14 (1)	12 (2)
Donor/Recipient sex match			
Male-Male	2771 (33)	428 (35)	176 (33)
Male-Female	1786 (21)	248 (20)	106 (20)
Female-Male	2124 (25)	279 (23)	130 (25)

Refresh date: April 2021

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Female-Female	1660 (20)	258 (21)	104 (20)
CB - recipient M	19 (<1)	14 (1)	6 (1)
CB - recipient F	10 (<1)	4 (<1)	4 (1)
Unknown	4 (N/A)	1 (N/A)	0 (N/A)
Year of transplant			
2006-2010	581 (7)	65 (5)	47 (9)
2011-2015	3626 (43)	472 (38)	194 (37)
2016-2020	4167 (50)	695 (56)	285 (54)
Follow-up among survivors, Months			
N Eval	5080	737	320
Median (Range)	37 (1-148)	35 (3-124)	37 (2-143)